NeuroOne Medical Technologies Corp (NMTC) is now in the Fair zone, suggesting that its current forward PS ratio of 3.82 is considered Fairly compared with the five-year average of -3.29. The fair price of NeuroOne Medical Technologies Corp (NMTC) is between 0.62 to 0.82 according to relative valuation method.

Relative Value

Fair Zone

0.62-0.82

Current Price：0.81

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is NeuroOne Medical Technologies Corp (NMTC) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

NeuroOne Medical Technologies Corp (NMTC) has a current Price-to-Book (P/B) ratio of 6.03. Compared to its 3-year average P/B ratio of 8.49, the current P/B ratio is approximately -29.05% higher. Relative to its 5-year average P/B ratio of 7.21, the current P/B ratio is about -16.38% higher. NeuroOne Medical Technologies Corp (NMTC) has a Forward Free Cash Flow (FCF) yield of approximately -6.79%. Compared to its 3-year average FCF yield of -33.79%, the current FCF yield is approximately -79.89% lower. Relative to its 5-year average FCF yield of -32.71%, the current FCF yield is about -79.23% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NMTC competitors is 2.58, providing a benchmark for relative valuation. NeuroOne Medical Technologies Corp Corp (NMTC.O) exhibits a P/S ratio of 3.82, which is 48.28% above the industry average. Given its robust revenue growth of -53.90%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NMTC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NMTC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NMTC currently overvalued or undervalued?

What is NeuroOne Medical Technologies Corp (NMTC) fair value?

NMTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of NeuroOne Medical Technologies Corp (NMTC) is between 0.62 to 0.82 according to relative valuation method.

How does NMTC's valuation metrics compare to the industry average?

The average P/S ratio for NMTC's competitors is 2.58, providing a benchmark for relative valuation. NeuroOne Medical Technologies Corp Corp (NMTC) exhibits a P/S ratio of 3.82, which is 48.28% above the industry average. Given its robust revenue growth of -53.90%, this premium appears unsustainable.

What is the current P/B ratio for NeuroOne Medical Technologies Corp (NMTC) as of Mar 04 2026?

As of Mar 04 2026, NeuroOne Medical Technologies Corp (NMTC) has a P/B ratio of 6.03. This indicates that the market values NMTC at 6.03 times its book value.

What is the current FCF Yield for NeuroOne Medical Technologies Corp (NMTC) as of Mar 04 2026?

As of Mar 04 2026, NeuroOne Medical Technologies Corp (NMTC) has a FCF Yield of -6.79%. This means that for every dollar of NeuroOne Medical Technologies Corp's market capitalization, the company generates -6.79 cents in free cash flow.

What is the current Forward P/E ratio for NeuroOne Medical Technologies Corp (NMTC) as of Mar 04 2026?

As of Mar 04 2026, NeuroOne Medical Technologies Corp (NMTC) has a Forward P/E ratio of -5.50. This means the market is willing to pay $-5.50 for every dollar of NeuroOne Medical Technologies Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for NeuroOne Medical Technologies Corp (NMTC) as of Mar 04 2026?

As of Mar 04 2026, NeuroOne Medical Technologies Corp (NMTC) has a Forward P/S ratio of 3.82. This means the market is valuing NMTC at $3.82 for every dollar of expected revenue over the next 12 months.

NMTC Valuation